P. Balakumar and Manjeet Singh
International Journal of Pharmacology, 2006, 2(5), 543-548.
The male Wistar rats were anaesthetized with thiopentone sodium (35 mg kg-1, i.p.,) and were subjected to Partial Abdominal Aortic Constriction (PAAC) for 4 wk. 3-aminobenzamide (10, 20 mg kg-1 i.p., b.i.d) treatment was started three days before surgery and it was continued for 4 weeks after surgery. The Left Ventricular (LV) hypertrophy and LV dysfunction were assessed by measuring ratio of LV weight to body weight (LVW/BW), LV wall thickness (LVWT), LV collagen content, protein content, RNA concentration, Left Ventricular Developed Pressure (LVDP), rate of pressure development (dp/dtmax) and rate of pressure decay (dp/dtmin). Further, Venous Pressure (VP) and Mean Arterial Blood Pressure (MABP) were recorded. The PAAC produced LV hypertrophy by increasing LVW/BW, LVWT, LV protein content and LV RNA concentration. Further, PAAC was noted to produce LV dysfunction by decreasing LVDP, dp/dtmax, dp/dtmin and increasing LV collagen content. Moreover, PAAC has significantly increased VP and MABP. 3-Aminobenzamide, a PARP inhibitor markedly attenuated PAAC-induced LV hypertrophy, LV dysfunction, increase in VP and MABP. These results suggest that 3-aminobenzamide prevented PAAC-induced cardiac hypertrophy and LV dysfunction which may be due to inhibition of PARP.
ASCI-ID: 23-265
International Journal of Pharmacology, 2019, 15(3), 311-317.
Role of Carnitine on Hematological Parameters and Attenuation of Cardiac (Pro)renin Receptor and Caspase-3 Expression in Hypoglycemia-induced Cardiac HypertrophyInternational Journal of Pharmacology, 2020, 16(3), 191-200.
Bisacurone Ameliorated Pressure Overload-Induced Cardiac Hypertrophy in Experimental Rats Through Inhibition of Oxidative Stress and Bax/Caspase-3 PathwayInternational Journal of Pharmacology, 2022, 18(3), 415-427.
Pharmacology, 2007, 80(2-3), 177. DOI: 10.1159/000103917
PPAR Ligands: Are They Potential Agents for Cardiovascular Disorders?Pharmacology, 2007, 80(1), 1. DOI: 10.1159/000102594
Effect of Mast Cell Stabilizers in Hyperhomocysteinemia-induced Cardiac Hypertrophy in RatsJournal of Cardiovascular Pharmacology, 2008, 51(6), 596. DOI: 10.1097/FJC.0b013e31817ae60f
Effect of Fenofibrate in Pressure Overload-induced Experimental Cardiac HypertrophyInternational Journal of Biological Chemistry, 2007, 1(2), 104. DOI: 10.3923/ijbc.2007.104.110
Peroxisome Proliferator Activated Receptor Agonists: Emerging Therapy for Cardiovascular ComplicationsJournal of Pharmacology and Toxicology, 2007, 2(3), 205. DOI: 10.3923/jpt.2007.205.219
Recent Advances in Pharmacotherapy for Heart Failure: Future DirectionsTrends in Medical Research, 2007, 2(2), 61. DOI: 10.3923/tmr.2007.61.71
Experimental Models for Vascular Endothelial DysfunctionTrends in Medical Research, 2007, 2(1), 12. DOI: 10.3923/tmr.2007.12.20
Hyperhomocysteinemia and Cardiovascular Disorders: Is There a Correlation?Trends in Medical Research, 2007, 2(4), 160. DOI: 10.3923/tmr.2007.160.166
Resident Cardiac Mast Cells: Are They the Major Culprit in the Pathogenesis of Cardiac Hypertrophy?Basic & Clinical Pharmacology & Toxicology, 2007, 0(0), 071031053307001. DOI: 10.1111/j.1742-7843.2007.00147.x
Potential target sites to modulate vascular endothelial dysfunction: Current perspectives and future directionsToxicology, 2008, 245(1-2), 49. DOI: 10.1016/j.tox.2007.12.011
Transcriptome-based repurposing of apigenin as a potential anti-fibrotic agent targeting hepatic stellate cellsScientific Reports, 2017, 7(1), . DOI: 10.1038/srep42563
Anti-blastocystosis activity of antioxidant coated ZIF-8 combined with mesoporous silicas MCM-41 and KIT-6Scientific Reports, 2022, 12(1), . DOI: 10.1038/s41598-022-10397-4
Curcumin induces cortico-hippocampal neuronal reshaping and memory improvements in aged miceJournal of Chemical Neuroanatomy, 2022, 121(), 102091. DOI: 10.1016/j.jchemneu.2022.102091
Graphene oxide-chitosan composite material as adsorbent in removing methylene blue dye from synthetic wastewaterMaterials Today: Proceedings, 2022, (), . DOI: 10.1016/j.matpr.2022.03.092